Baird Downgrades DexCom to Neutral, Lowers Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Jeff Johnson has downgraded DexCom (NASDAQ:DXCM) from Outperform to Neutral and lowered the price target from $161 to $80.
August 05, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Baird analyst Jeff Johnson downgraded DexCom from Outperform to Neutral and significantly lowered the price target from $161 to $80.
The downgrade from Outperform to Neutral and the substantial reduction in the price target from $161 to $80 by a reputable analyst is likely to negatively impact investor sentiment and the stock price of DexCom in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100